Clinical Trial Update: Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating APR-246 in combination with pembrolizumab in solid tumors has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Gastric Cancer
• Non-small Cell Lung Cancer
• Solid Tumors
• Urothelial Carcinoma

Drugs mentioned

• APR-246 (eprenetapopt)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Aprea Therapeutics | Conditions: Bladder Cancer, Gastric Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-05-13